Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;11(1):53–68. doi: 10.1111/j.1527-3458.2005.tb00035.x

An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress‐Related Disorders

Claudine Serradeil‐Le Gal 1,✉, Jean Wagnon 2, Bernard Tonnerre 2, Richard Roux 2, Georges Garcia 2, Guy Griebel 3, Alain Aulombard 4
PMCID: PMC6741711  PMID: 15867952

ABSTRACT

Vasopressin (AVP) and corticotropin‐releasing factor (CRF) are key mediators in the organism's neuro‐adaptive response to stress. Through pituitary and central vasopressin V1b receptors, AVP participates in the control of the hypothalamic‐pituitary‐adrenal axis (HPA) and is involved in various emotional processes. SSR149415 is the first selective, orally active vasopressin V1b receptor antagonist yet described. It is a competitive antagonist with nanomolar affinity for animal and human V1b receptors and displays a highly selective profile with regard to a large number of receptors or enzymes. In vitro, SSR149415 potently antagonizes functional cellular events associated with V1b receptor activation by AVP, such as intracellular Ca2+ increase or proliferation in various cell systems. Pharmacological studies, performed by measuring ACTH secretion induced by various stimulants such as hormones (AVP or AVP + CRF) or physical stress (restraint or forced swimming stress and dehydration) in conscious rats or mice, confirm the antagonist profile of SSR149415 and its efficacy in normalizing ACTH secretion in vivo. SSR149415 is active by the oral route, at doses from 3 mg/kg, it potentiates CRF effect and displays a long‐lasting oral effect in the different models. At 10 mg/kg p.o. its duration of action is longer than 4 h. This molecule also decreases anxiety and exerts marked antidepressant‐like activity in several predictive animal models. The anxiolytic effects of SSR149415 have been demonstrated in various Generalized Anxiety Disorders (GAD) models (four‐plate, punished drinking, elevated plus‐maze, light dark, mouse defense test battery, fear‐potentiated startle and social interaction tests). It is as effective as the benzodiazepine diazepam in the acute stress exposure test. SSR149415 has similar efficacy to the reference antidepressant drug, fluoxetine, in acute (forced‐swimming) and chronic (chronic mild stress and subordination stress) situations in rodents. SSR149415 also reduces offensive aggression in the resident‐intruder model in mice and hamsters. Depending on the model, the minimal effective doses are in the range of 1‐10 mg/kg i.p. or 3‐10 mg/kg p.o. SSR149415 is devoid of adverse effects on motor activity, sedation, memory or cognitive functions and produces no tachyphylaxis when administered repeatedly. It is well‐tolerated in animals and humans and exhibits an adequate ADME profile. Thus, SSR149415 is a new dual anxiolytic/antidepressant compound, which appears to be free of the known side effects of classical anxiolytic/antidepressant drugs. Clinical trials are in progress, they will hopefully demonstrate its therapeutical potential for treating stress‐related disorders.

Keywords: Anxiety, Depression, SSR149415, Stress, V1b receptor antagonist, Vasopressin

Full Text

The Full Text of this article is available as a PDF (175.2 KB).

REFERENCES

  • 1. Aguilera G, Rabadan‐Diehl C. Vasopressinergic regulation of the hypothalamic‐pituitary‐adrenal axis: Implications for stress adaptation. Regul Pept 2000;96:23–29. [DOI] [PubMed] [Google Scholar]
  • 2. Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P. Blockade of CRF(1) or V(1b) receptors reverses stress‐induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2003;9:278–286. [DOI] [PubMed] [Google Scholar]
  • 3. Barberis C, Morin D, Durroux T, et al. Molecular pharmacology of AVP and OT receptors and therapeutic potential. Int Drug Newsmag Drug News Persp 1999;12:279–292. [Google Scholar]
  • 4. Blanchard R, Griebel G, Gully D, et al. Effect of the V1b receptor antagonist, SSR149415 and the CRF1 receptor antagonist, SSR125543a in the V1b suggest antidepressant‐like activity. Soc Neurosci Meeting 2002;307.3.
  • 5. Blanchard R, Griebel G, Yang M, Markham C, Farrokhi C, Blanchard D. The V1b receptor antagonist SSR149415 reduces aggressive behaviors in hamsters. Soc Neurosci 2003:217.3.
  • 6. De Keyzer Y, Auzan F, Beldford C, Thibonnier M, Bertagna X, Clauser E. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994;356:215–220. [DOI] [PubMed] [Google Scholar]
  • 7. De Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X. Overexpression of vasopressin (V3) and corticotrophin‐releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol 1998;49:475–482. [DOI] [PubMed] [Google Scholar]
  • 8. De Vries GJ, Buijs RM. The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 1983;273:307–317. [DOI] [PubMed] [Google Scholar]
  • 9. de Wied D. Preservation of a conditioned avoidance response by lysine vasopressin. J Endocrinol 1970;48:XLV–XLVI. [PubMed] [Google Scholar]
  • 10. de Wied D, Sigling HO. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 2002;4:453–468. [DOI] [PubMed] [Google Scholar]
  • 11. de Winter RF, van Hemert AM, DeRijk RH, et al. Anxious‐retarded depression: Relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003;28:140–147. [DOI] [PubMed] [Google Scholar]
  • 12. Derick S, Pena A, Durroux T, et al. Key amino acids located within the transmembrane domains V and VII account for the pharmacological specificity of the human V1b vasopressin receptors. Mol Endocrinol 2004;18:2777–2789. [DOI] [PubMed] [Google Scholar]
  • 13. Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin‐releasing hormone (CRH), arginine vasopressin (AVP), CRH + AVP, and CRH + metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996;81:2934–2941. [DOI] [PubMed] [Google Scholar]
  • 14. Duman RS, Malberg J, Nakagawa S. Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmacol Exp Ther 2001;299:401–407. [PubMed] [Google Scholar]
  • 15. Folny V, Raufaste D, Lukovic L, et al. Pancreatic vasopressin V1b receptors: Characterization in In‐R1‐G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab 2003;285:E566–E576. [DOI] [PubMed] [Google Scholar]
  • 16. Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982;299:355–357. [DOI] [PubMed] [Google Scholar]
  • 17. Griebel G, Simiand J, Serradeil‐Le Gal C, et al. Anxiolytic‐ and antidepressant‐like effects of the non‐peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress‐related disorders. Proc Natl Acad Sci USA 2002;99:6370–6375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Griebel G, Simiand J, Stemmelin J, Gal Serradeil‐Le, Steiberg R. The vasopressin V1b receptor as a therapeutic target in stress‐related disorders. Curr Drug Target CNS Neurol Disord 2003;2:191–200. [DOI] [PubMed] [Google Scholar]
  • 19. Hernando F, Schoots O, Lolait SJ, Burbach JP. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001;142:1659–1668. [DOI] [PubMed] [Google Scholar]
  • 20. Higashihara F, Tanoue A, Egashira N, et al. Vasopressin V1b receptor knockout mice exhibit impairment of prepulse inhibition. J Pharmacol Sci 2004;94:204–211. [Google Scholar]
  • 21. Holsboer F. The role of peptides in treatment of psychiatric disorders. J Neural Transm Suppl 2003;64:17–34. [DOI] [PubMed] [Google Scholar]
  • 22. Holsboer F, Barden N. Antidepressants and hypothalamic‐pituitary‐adrenocortical regulation. Endocrinol Rev 1996;17:187–205. [DOI] [PubMed] [Google Scholar]
  • 23. Hugin‐Flores ME, Steimer T, Schulz P, Valloton MB, Aubert ML. Chronic corticotropin‐releasing hormone and vasopressin regulate corticosteroid receptors in rat hippocampus and anterior pituitary. Brain Res 2003;976:159–170. [DOI] [PubMed] [Google Scholar]
  • 24. Koob GF, Bloom FE. Behavioral effects of neuropeptides: Endorphins and vasopressin. Annu Rev Physiol 1982;44:571–582. [DOI] [PubMed] [Google Scholar]
  • 25. Lolait SJ, O'Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995;92:6783–6787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. North WG, Fay MJ, Longo KA, Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res 1998;58:1866–1871. [PubMed] [Google Scholar]
  • 27. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin‐ and oxytocin‐expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137–143. [DOI] [PubMed] [Google Scholar]
  • 28. Ring RH, Malberg J, Li J, et al. Neurochemical and behavioral characterization of a vasopressin V3 (V1B) receptor antagonist. Soc Neurosci 2004;359.9.
  • 29. Roux R, Serradeil‐Le Gal C, Tonnerre B, Wagnon J. Novel 1,3‐dihydro‐2H‐indol‐2‐one derivatives, preparation method and pharmaceutical compositions containing them. [PCT/WO 01/5130] A2.02.082001.
  • 30. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805–809. [DOI] [PubMed] [Google Scholar]
  • 31. Serradeil‐Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996;98:2729–2738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Serradeil‐Le Gal C, Wagnon J, Garcia C, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 1993;92:224–231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Serradeil‐Le Gal C, Wagnon J, Simiand J, et al. Characterization of (2S,4R)‐1‐[5‐chloro‐1‐[(2,4‐dimethoxyphenyl)sulfonyl]‐3‐(2‐methoxy‐phenyl)‐2‐oxo‐2,3‐dihydro‐1H‐indol‐3‐yl]‐4‐hydroxy‐N,N‐dimethyl‐2‐pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 2002;300:1122–1130. [DOI] [PubMed] [Google Scholar]
  • 34. Stemmelin J, Lukovic L, Soubrie P, Griebel G. The antidepressant‐like effects of the V1b receptor antagonist SSR149415 in rats are mediated by the lateral septum and the central nucleus of the amygdala. Soc Neurosci 2003;217.2.
  • 35. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994;269:27088–27092. [PubMed] [Google Scholar]
  • 36. Surget A, Saxe M, Griebel G, Hen R, Belzung C. Hippocampal neurogenesis contributes to the efficacy of tricyclic antidepressants (imipramine), SSRIs (fluoxetine) and the V1b antagonist (SSR149415) following a chronic unpredictable stress procedure in mice. Int J Neuropsychopharmacol 2004;7:SS359. [Google Scholar]
  • 37. Thibonnier M, Preston JA, Dulin N, Wikins PL, Bert‐Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: Ligand binding profile and density‐dependent signaling pathways. Endocrinology 1997;138:4109–4122. [DOI] [PubMed] [Google Scholar]
  • 38. Vaccari C, Lolait SJ, Ostrowski NL. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 1998;139:5015–5033. [DOI] [PubMed] [Google Scholar]
  • 39. Wersinger SR, Ginns EI, O'Carroll AM, Lolait SJ, Young WS III Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 2002;7:975–984. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES